| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
NMDA Receptor
L-Glutamic acid-15N itself does not have a traditional biological target; it is a stable isotope-labeled tracer. The parent compound L-Glutamic acid is a non-essential amino acid that is the most abundant excitatory neurotransmitter in the vertebrate nervous system. L-Glutamic acid-15N is used to track nitrogen metabolism, including its incorporation into other amino acids and neurotransmitters, through isotopic tracing experiments. |
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
L-Glutamic acid-15N does not exhibit direct in vitro biological activity as it is an isotopically labeled tracer. However, the parent compound L-Glutamic acid is a non-essential amino acid and neurotransmitter. In cell culture studies, L-Glutamic acid-15N is used to trace nitrogen metabolic pathways by monitoring the incorporation of 15N into downstream metabolites such as glutamine, alanine, and other amino acids using mass spectrometry. |
| ln Vivo |
L-Glutamic acid-15N is not administered as a therapeutic agent; it is used as a metabolic tracer in in vivo studies. When administered to animal models, it allows researchers to track nitrogen flow through various metabolic pathways, including amino acid metabolism and neurotransmitter synthesis. The labeled compound is used to study nitrogen metabolism in healthy and diseased states, including neurological and metabolic disorders.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for L-Glutamic acid-15N are not applicable, as it is a metabolic tracer rather than a bioactive compound. Quality control assays involve HPLC or mass spectrometry to verify isotopic purity (≥98 atom % 15N) and chemical purity. The compound is also tested for solubility and stability under recommended storage conditions. It is soluble in water.
|
| Cell Assay |
In vitro cellular assays for L-Glutamic acid-15N involve metabolic tracing studies rather than traditional bioactivity assays. Cells are cultured in media containing L-Glutamic acid-15N, and the incorporation of 15N into metabolites such as glutamine, alanine, and other amino acids is measured by LC-MS or GC-MS. These studies allow researchers to quantify nitrogen flux through various metabolic pathways, including the TCA cycle and amino acid synthesis.
|
| Animal Protocol |
In vivo animal studies for L-Glutamic acid-15N involve metabolic tracing experiments. Animals are administered the labeled glutamic acid via oral or intravenous routes. Blood, tissues, and excreta are collected at various time points, and the 15N enrichment in metabolites is measured by mass spectrometry. These studies provide insights into whole-body nitrogen metabolism, including protein turnover and amino acid utilization.
|
| ADME/Pharmacokinetics |
L-Glutamic acid-15N has a molecular formula of C5H9NO4 and a molecular weight of 148.12. It has a purity of ≥98% and an isotopic enrichment of ≥98 atom % 15N. It appears as a solid. The compound is stable under recommended storage conditions. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of L-Glutamic acid-15N is not extensively characterized, as it is a stable isotope-labeled tracer rather than a therapeutic agent. The parent compound L-Glutamic acid is a naturally occurring amino acid that is generally recognized as safe. Standard safety data for handling isotopically labeled compounds in laboratory settings would apply. L-Glutamic acid-15N is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
L-Glutamic acid-15N (CAS 21160-87-2) is the 15N-labeled form of L-Glutamic acid, where the single nitrogen atom is replaced with nitrogen-15. L-Glutamic acid is a non-essential amino acid that is the most abundant excitatory neurotransmitter in the vertebrate nervous system. This labeled compound is used as a tracer in metabolic studies to track nitrogen flow and utilization in amino acid metabolism. It is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
C5H915NO4
|
|---|---|
| Molecular Weight |
148.12
|
| Exact Mass |
148.05
|
| CAS # |
21160-87-2
|
| Related CAS # |
L-Glutamic acid;56-86-0
|
| PubChem CID |
10942598
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
205ºC (dec.)(lit.)
|
| LogP |
-3.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
145
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(CC(=O)O)[C@@H](C(=O)O)[15NH2]
|
| InChi Key |
WHUUTDBJXJRKMK-OGWWSMAPSA-N
|
| InChi Code |
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1/i6+1
|
| Chemical Name |
(2S)-2-(15N)azanylpentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 5 mg/mL (33.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7513 mL | 33.7564 mL | 67.5128 mL | |
| 5 mM | 1.3503 mL | 6.7513 mL | 13.5026 mL | |
| 10 mM | 0.6751 mL | 3.3756 mL | 6.7513 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
